title: Gonorrhoea in men: clinical and diagnostic aspects.
abstract: OBJECTIVE
  To review the features of gonococcal infection in men in the 1990s.
  
  
  METHODS
  A retrospective study of all men with gonorrhoea presenting to an inner city department of genitourinary medicine in the years 1990 to 1992.
  
  
  RESULTS
  1749 cases of gonorrhoea were seen in 1382 men. A high incidence of gonorrhoea was found in attenders of African or Caribbean extraction. In 228 men with a known date of infection, the incubation period, a mean of 8.3 days, was longer than previously described. The mean infectious period was 12.0 days. By 14 days 86.2% of men had developed symptoms. Of 1615 men with urethral infection 81.9% complained of discharge, while dysuria occurred in 52.8%. Discharge with dysuria were present in only 48.1% of patients. In 10.2% episodes of urethral infection the patients had no symptoms referable to their gonorrhoea. Urethral gonorrhoea was diagnosed by microscopy in 94.4% of symptomatic men and in only 81.1% of asymptomatic men. Microscopy of rectal samples were positive in 46.4% of cases. In this population, a dose of 2 g of ampicillin with 1 g of probenecid gave a high cure rate of gonorrhoea as long as infection was not due to penicillinase-producing organisms.
  
  
  CONCLUSIONS
  These data suggest that the incubation and infectious period of urethral gonorrhoea has increased compared with previous studies and that symptoms have altered. Only 48.1% of men described the classical symptoms of discharge with dysuria. Microscopy of urethral smears remains useful in symptomatic men but is less sensitive in those without symptoms.
authors.affiliation: Department of Genitourinary Medicine, Radcliffe Infirmary, UK.
authors.forename: J
authors.initials: J
authors.lastname: Sherrard
authors.forename: D
authors.initials: D
authors.lastname: Barlow
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000150:complications; D002692:Chlamydia trachomatis; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006069:Gonorrhea / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000208:ethnology; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D011339:Probenecid / Q000627:therapeutic use; D012002:Rectal Diseases / Q000382:microbiology; D012189:Retrospective Studies; D012725:Sexual Behavior; D014195:Travel; D016896:Treatment Outcome; D014522:Urethral Diseases / Q000382:microbiology; D014528:Uricosuric Agents / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014528:Uricosuric Agents; D000667:Ampicillin; D011339:Probenecid